Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Markets Earnings Roundup: GlaxoSmithKline (Part 4)

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline CEO Andrew Witty took a question on the China compliance investigation and quickly moved on in an earnings call also thin on emerging market plans. However, the earnings release added a bit of detail on both fronts, including up-to-date details on regulatory aspects outside of China.

You may also be interested in...



GSK’s Post-Advair Day Has Dawned, But Breo And Anoro Not Yet Shining

Decline in Advair sales to cointinue for several years as the portfolio transitions to new products, which have faced reimbursement challenges.

List Ahead For Southeast Asia Pharma In 2015

PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.

Southeast Asia 2014: Distribution, Manufacturing To The Fore

Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC087703

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel